

**Efforts to move into overseas markets:  
Collaboration with JCR Pharmaceuticals Co., Ltd. on global  
development of new drugs in the ultra-rare disease area**

---

In October 2022, MEDIPAL and JCR Pharmaceuticals Co., Ltd. executed a memorandum granting exclusive negotiation rights for the global commercialization outside Japan of four new drug candidates being developed by JCR Pharmaceuticals for ultra-rare lysosomal storage diseases (LSDs).

JCR Pharmaceuticals Co., Ltd. is focused on the research and development of several products for the treatment of rare LSDs that use J-Brain Cargo, JCR's proprietary blood brain barrier (BBB) penetration technology.

Ultra-rare diseases have very small patient populations, which generally makes new drug development challenging. The MEDIPAL Group will support new drug development in these ultra-rare disease fields.

